API
< Back to all clusters
[BUSINESS] · United States · 19 sources

started · updated

Eli Lilly raises revenue guidance following strong Q3 results

Eli Lilly reported third quarter revenue of $24.4 billion, a 39% increase compared to the previous year. This growth was primarily driven by high demand for its diabetes and obesity treatments, Mounjaro and Zepbound, which recorded sales of $10.7 billion and $5.3 billion, respectively.

Following these results, the company raised its 2026 annual revenue guidance to a range of $91 billion to $92 billion, up from the previous estimate of $85 billion to $87 billion. Despite the revenue boost, Eli Lilly lowered its adjusted earnings per share guidance for 2026 to between $35.00 and $36.00, citing costs related to recent acquisitions.

The company also announced an agreement to acquire Merida Biosciences, which focuses on treatments for autoimmune diseases and allergies. Additionally, Lilly completed the acquisition of AtaiBeckley, a firm targeting depression therapies.

Entities

AtaiBeckley · David Ricks · Eli Lilly · Eli Lilly and Company · Merida Biosciences · Mounjaro · Zepbound

Claims

What the coverage asserts, and how many sources carry each claim.

Sources